Erez Israeli, chief executive officer of Dr. Reddy's Laboratories, provides insight on the company’s generic version of semaglutide, which entered the Canadian market in May 2026.
Erez Israeli
Advertisement
Erez Israeli is chief executive officer of Dr. Reddy's Laboratories.
Articles by Erez Israeli
Advertisement
Latest Updated Articles
Advertisement
Advertisement